The Inclusion of a Gemcitabine + Nab-paclitaxel Regimen as a 2^nd Line Treatment for Advanced Pancreatic Cancer – First Experience

Česká verzia

Authors: M. Vočka; L. Petruželka
Authors place of work: Onkologická klinika 1. LF UK a VFN v Praze
Published in the journal: Klin Onkol 2017; 30(6): 452-455
Category: Původní práce
doi: https://doi.org/10.14735/amko2017452

Summary

Introduction:
Pancreatic cancer is the fourth leading cause of cancer-related death worldwide. The outcomes at all stages of the disease are the worst among patients with solid tumors.

Patients and Methods:
Analyses were conducted on 19 patients treated with gamcitabine + nab-paclitaxel for locally advanced or metastatic pancreatic cancer as a second line treatment between October, 2014, and December, 2016, at Department of Oncology of First Faculty of Medicine and General University Hospital in Prague. Patients were treated with gemcitabine (1,000 mg/sqm) + nab-paclitaxel (125 mg/sqm) at days 1, 8 and 15 of each 28-day cycle. Antitumor efficacy (disease control rate (DCR), time to progression (TTP), and overall survival (OS)) and adverse events were monitored.

Results:
Disease control according to RECIST criteria was achieved in nine cases (56.3%, two partial regressions were observed). The median TTP was 5.5 months and median OS was 10.1 months.

Conclusion:
In patients with advanced or metastatic pancreatic cancer with good performance statuses (0–1) gemcitabine + nab-paclitaxel as a second line treatment led to a prolongation in time to progression and higher overall survival with good quality of life.

Key words:
pancreatic cancer – gemcitabine – nab-paclitaxel – efficiency – toxicity

This project was supported by grant PROGRES-Q-25/LF1, The League Against Cancer a AZV CR 15-28188A.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
11. 7. 2017

Accepted:
20. 9. 2017

Zdroje

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (1): 5–29. doi: 10.3322/caac.21254.

2. Svod.cz. [online]. Dostupné na: www.svod.cz.

3. Hidalgo M. Pancreatic Cancer. N Engl J Med 2010; 362 (17): 1605–1617. doi: 10.1056/NEJMra0901557.

4. Carrato A, Falcone A, Ducreux M et al. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. J Gastrointest Cancer 2015; 46 (3): 201–211. doi: 10.1007/s12029-015-9724-1.

5. Glimelius B, Hoffman K, Sjödén PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7 (6): 593–600.

6. Burris IHA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15 (6): 2403–2413. doi: 10.1200/JCO.1997.15.6.2403.

7. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19): 1817–1825. doi: 10.1056/NEJMoa1011923.

8. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreaticcancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369 (18): 1691–1703. doi: 10.1056/NEJMoa1304369.

9. Vočka M, Petruželka L. Zařazení režimu FOLFIRINOX do algoritmu léčby metastazujícího karcinomu slinivky břišní – první zkušenosti. Gastroent Hepatol 2014; 68 (5): 436–440. doi: 10.14735/amgh2014436.

10. Vočka M, Petruželka L. Modifikovaný FOLFIRINOX v léčbě karcinomu pankreatu – účinnost a toxicita. Gastroent Hepatol 2016; 70 (5): 413–417. doi: 10.14735/amgh2016413.

11. Smyth EN, Bapat B, Ball DE et al. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. Clin Ther 2015; 37 (6): 1301–1316. doi: 10.1016/j.clinthera.2015.03.016.

12. Bertocchi P, Abeni C, Meriggi F et al. Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis. Rev Recent Clin Trials 2015; 10 (2): 142–145.

13. Pelzer U, Schwaner I, Stieler J et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47 (11): 1676–1681. doi: 10.1016/j.ejca.2011.04.011.

14. Oettle H, Riess H, Stieler JM et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32 (23): 2423–2429. doi: 10.1200/JCO.2013.53.6995.

15. Wang-Gillam A, Li CP, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387 (10018): 545–557. doi: 10.1016/S0140-6736 (15) 00986-1.